Merck, On Its Alzheimer's Drug Program, Tells Benzinga Too Early To Speculate What Verubecestat Trial Results Mean For Validity Of 'Amyloid Hypothesis', Hopes By Evaluating Drug In People W/Less Impairment Will Be Able To Slow Disease Progression